Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 3, 2004, Pages 965-974

  Koukouritaki, Sevasti B ^a   Manro, Jason R ^b   Marsh, Sandra A ^b   Stevens, Jeffrey C ^b   Rettie, Allan E ^c   McCarver, D Gail ^a   Hines, Ronald N ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DICLOFENAC; MEPHENYTOIN;

ADOLESCENT; ADULT; AGE; AGING; ARTICLE; CATALYSIS; CHILD; DEVELOPMENTAL BIOLOGY; EMBRYO; ENZYME ACTIVITY; FETUS; HUMAN; HUMAN TISSUE; INFANT; LIVER MICROSOME; NEWBORN; ONTOGENY; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ARYL HYDROCARBON HYDROXYLASES; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; MIXED FUNCTION OXYGENASES;

EID: 1342344547     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.060137     Document Type: Article

References (34)

1. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, and Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530.
2. Capdevila JH, Falck JR and Estabrook RW (1992) Cytochrome P450 and the arachidonate cascade. FASEB J 6:731-736.
3. Cereghini S (1996) Liver-enriched transcription factors and hepatocyte differentiation. FASEB J 10:267-282.
4. Chen Y, Ferguson SS, Negishi M, and Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316-324.
5. Edwards RJ, Adams DA, Watts PS, Davies DS, and Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56:377-387.
6. Fan PW, Gu C, Marsh SA, and Stevens JC (2003) Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor. Drug Metab Dispos 31:28-36.
7. Ferguson SS, LeCluyse EL, Negishi M, and Goldstein JA (2002) Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol 62:737-746.
8. Gerbal-Chaloin S, Daujat M, Pascussi J-M, Pichard-Garcia L, Vilarem M-J, and Maurel P (2002) Transcriptional regulation of CYP2C9 gene: role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 277:209-217.
9. Giancarlo GM, Venkatakrishnan K, Granda BW, Von Moltke LL, and Greenblatt DJ (2001) Relative contribution of CYP2C9 and -2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole and ticlopidine. Eur J Clin Pharmacol 57:31-36.
10. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
11. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
12. Gonzalez FJ (1990) Molecular genetics of the P-450 superfamily. Pharmacol Ther 45:1-38.
13. Haining RL, Hunter AP, Veronese ME, Trager WF, and Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458.
14. Hines RN and McCarver DG (2002) The ontogeny of human drug metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
15. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, and Moore DD (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100:4156-4161.
16. Ibeanu GC and Goldstein JA (1995) Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 34:8028-8036.
17. Kaminsky LS and Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
18. Kamiya A, Inoue Y, and Gonzalez FJ (2003) Role of the hepatocyte nuclear factor 4a in control of the pregnane X receptor during fetal liver development. Hepatology 37:1375-1384.
19. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, and Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9:71-90.
20. Klose TS, Blaisdell JA, and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295.
21. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Res 51:236-243.
22. Leemann TD, Transon C, Bonnabry P, and Dayer P (1993) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19:189-195.
23. Nagata T, Takahashi Y, Ishii Y, Asai S, Sugahara M, Nishida Y, Murata A, Chin M, Schichino H, Koshinaga T, et al. (2003) Profiling of genes differentially expressed between fetal liver and postnatal liver using high-density oligonucleotide DNA array. Int J Mol Med 11:713-721.
24. Rogers JF, Nafziger AN, and Bertino JS Jr (2002) Pharmacogenetics affects dosing, efficacy and toxicity of cytochrome P450-metabolized drugs. Am J Med 113:746-750.
25. Sadeque AJM, Thummel KE, and Rettie AE (1993) Purification of macaque liver flavin-containing monooxygenase: a form of the enzyme related immunochemically to an isozyme expressed selectively in adult human liver. Biochim Biophys Acta Protein Struct Mol Enzymol 1162:127-134.
26. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
27. Stevens JC, White RB, Hsu SH, and Martinet M (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J Pharmacol Exp Ther 282:1389-1395.
28. Tang W, Stearns RA, Wang RW, Chiu SH, and Baillie TA (1999) Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 12:192-199.
29. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
30. Treluyer J-M, Gueret G, Cheron G, Sonnier M, and Cresteil T (1997) Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in vitro correlation and inducibility. Pharmacogenetics 7:441-452.
31. Wei P, Zhang J, Dowhan DH, Han Y, and Moore DD (2002) Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2:117-126.
32. Wester MR, Lasker JM, Johnson EF, and Raucy JL (2000) CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 28:354-359.
33. Wrighton SA, Stevens JC, Becker GW, and Vandenbranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
34. Yasar Ü, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjöqvist F, and Dahl M-L (2001) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 57:729-735.